A citation-based method for searching scientific literature

Rengyun Liu, Tao Zhang, Guangwu Zhu, Mingzhao Xing. Nat Commun 2018
Times Cited: 80



Mingzhao Xing, Bryan R Haugen, Martin Schlumberger. Lancet 2013
Times Cited: 325




List of shared articles



Times cited

TERT Promoter Mutations and the 8th Edition TNM Classification in Predicting the Survival of Thyroid Cancer Patients.
Jun Park, Sungjoo Lee, Kyunga Kim, Hyunju Park, Chang-Seok Ki, Young Lyun Oh, Jung Hee Shin, Jee Soo Kim, Sun Wook Kim, Jae Hoon Chung,[...]. Cancers (Basel) 2021
4


The Coexistence of Genetic Mutations in Thyroid Carcinoma Predicts Histopathological Factors Associated With a Poor Prognosis: A Systematic Review and Network Meta-Analysis.
Ling Zhao, Lin Wang, Xiaomeng Jia, Xiaodong Hu, Ping Pang, Sitong Zhao, Yajing Wang, Jing Wang, Yingshi Zhang, Zhaohui Lyu. Front Oncol 2020
3

BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer.
Fei Wang, Shihua Zhao, Xiaopei Shen, Guangwu Zhu, Rengyun Liu, David Viola, Rossella Elisei, Efisio Puxeddu, Laura Fugazzola, Carla Colombo,[...]. J Clin Oncol 2018
26

How limited molecular testing can also offer diagnostic and prognostic evaluation of thyroid nodules processed with liquid-based cytology: Role of TERT promoter and BRAF V600E mutation analysis.
Marco Dell'Aquila, Vincenzo Fiorentino, Maurizio Martini, Sara Capodimonti, Tonia Cenci, Celestino Pio Lombardi, Marco Raffaelli, Alfredo Pontecorvi, Guido Fadda, Liron Pantanowitz,[...]. Cancer Cytopathol 2021
0

The ETS Inhibitor YK-4-279 Suppresses Thyroid Cancer Progression Independent of TERT Promoter Mutations.
Junyu Xue, Shiyong Li, Peijie Shi, Mengke Chen, Shuang Yu, Shubin Hong, Yanbing Li, Rengyun Liu, Haipeng Xiao. Front Oncol 2021
1

Genetic-guided Risk Assessment and Management of Thyroid Cancer.
Mingzhao Xing. Endocrinol Metab Clin North Am 2019
18